Abstract: Attenuated E. necatrix suitable for use in the production of a live vaccine is produced by passaging pathogenic E. necatrix in embryonated eggs for a sufficient number of passages i.e. from about 20 up to about 50 or more egg passages. The live egg-attenuated E. necatrix of the invention may be formulated in vaccines, e.g. feed or drinking water vaccines, for prevention and control of coccidiosis in poultry, usually with other strains of Eimeria (i.e. E. acervulina, E. brunetti, E. maxima, E. mivali, E. praecose and E. tenella) as live pathogenic strains thereof or preferably attenuated non-pathogenic lines thereof. In a preferred embodiment the egg-attenuated E. necatrix of the invention is formulated in a vaccine comprising attenuated, precocious E. acervulina.

Abstract: A method of treating the agent of human non-A, non-B hepatitis to render it incapable of causing infection which comprises heating said agent at about 60.degree. C. for about 10 hours and recovering the treated protective agent. Furthermore, this treated agent may be utilized as a vaccine, as, for example, inoculating chimpanzees by i.v. inoculation with the heat treated non-A, non-B agent and the animals have been found protected from later challenge by non-A, non-B hepatitis agent. Thus, the second part of the invention resides in the utilization of a heat-treated agent from human plasma later utilized to protect chimpanzees by incoluation and utilization as a vaccine.

Abstract: A spray of Candida kruseii is applied to the burned area of skin to allow for the healing of the burn and regeneration of the skin in the affected area. The Candida kruseii spray forms a crust over the affected area, allowing for a more rapid healing and skin regeneration in the affected area than is accomplished with prior burn control treatment. The Candida kruseii treatment is also effective with other open sores, such as varicose ulcers and decubitus ulcers.

Abstract: An improved method for preparing phenylphosphonous dihalide comprises reacting PCl.sub.3 and benzene in an electrically heated fluid bed reactor.

Abstract: Disclosed is a vaccine which prevents disease caused by Feline leukemia virus (FeLV) and which comprises a protease enzyme-inhibited, cell-free, ostensibly virusfree, in vitro produced feline leukemia neoantigens including FOCMA which evokes an immune response in cats by the appearance of antibodies thereto and a FeLV virion gp70 neoantigen which evokes an immune response in cats by the appearance of antibodies thereto. A novel method for making the vaccine is disclosed also.

Abstract: An inhalent allergen composition comprises an inhalent allergen and a saponin adjuvant. The inhalent allergen may be an extract of a grass pollen, such as rye grass, or a weed, such as ragweed. The saponin adjuvant may be an extract from the bark of the tree Quillaja Molina, and known as Quil-A.

Abstract: Influenza virus is extracted with a mixture of ether and ethanol, the aqueous and organic phases are separated and residual ether removed from the virus suspension under reduced pressure. The resulting product is useful as an influenza vaccine.

Abstract: Organic esters, e.g., linear esters, including diesters, are prepared by carbonylating a monoolefin with carbon monoxide and an alcohol in the presence of a catalytically effective amount of a catalyst comprising cobalt, a tertiary amine base and ruthenium.

Abstract: The present invention provides a process for the detection or determination of fibrin monomer in biological fluids, wherein the sample fluid is incubated with hydrophobic latex and the agglutination determined.The present invention also provides a reagent for the detection or determination of fibrin or fibrin monomer in biological fluids, wherein it contains hydrophobic latex.

Abstract: The preparation of a vaccine for immunization of canine and feline animals from inactivated HCP-SAD strain of rabis virus is disclosed.

Abstract: A pharmaceutical composition, for use in the desensitization therapy of humans allergic to non-infective allergens, comprises a non-infective allergen and an adjuvant consisting of a C.sub.10-22 alkyl ester of tyrosine or a pharmaceutically acceptable salt thereof.

Abstract: Novel N-hydroxyalkylated dicarboxylic acid bis(3,5-dicarbamoyl-2,4,6-triiodoanilides) have Formula I ##STR1## wherein R.sup.1 is a lower, linear or branched mono- or polyhydroxyalkyl residue,R.sup.2 is hydrogen, lower alkyl, or R.sup.1,R.sup.3 is lower mono- or dihydroxyalkyl, andX is a direct bond or linear or branched alkylene, which can be interrupted by one or more oxygen atoms or substituted by hydroxy or alkoxy groups.The novel dimeric compounds of Formula I possess good pharmacological and physicochemical properties making them very advantageous as radiopaque agents in all fields of application for water-soluble, iodine-containing X-ray contrast media.

Abstract: A biologically pure culture of the microorganism Micrococcus pseudoflaccidifex, ATCC No. 31970, which is capable of producing death in insects by mechanisms associated with wilt disease.

Abstract: Method for determination of the enzyme collagenase by reacting the enzyme with a peptide or peptolide substrate having the following amino acid sequences:R.sub.1 -Pro-Leu-Gly-Ile-Leu-Gly-Leu-R.sub.2,R.sub.1 -Gly-Pro-Leu-Gly-Ile-Leu-Gly-Ala-R.sub.2,R.sub.1 -Pro-Leu-Gly(O-Ile)-Leu-R.sub.2,R.sub.1 -Pro-Leu-Gly(O-Leu)-Leu-R.sub.2, andR.sub.1 -Pro-Leu-Gly(O-Leu)-Ala-R.sub.2,wherein R.sub.1 is H or N-protecting group, and R.sub.2 is terminal amide, carboxyl or ester group.

Abstract: New bronchospasmolytically active compounds exhibiting long duration of action and reduced undesired side effects of the structural formula ##STR1## and therapeutically acceptable salts thereof, in which formula R is selected from the group consisting of --C(CH.sub.3).sub.3, ##STR2## R.sup.1 is selected from the group consisting of H and R.sup.2, R.sup.2 represents the radical of the formula ##STR3## wherein R.sup.3 is selected from the group consisting of (a) H(b) alkyl groups containing 1-3 carbon atoms ##STR4## wherein R.sup.5 is selected from the group consisting of (e) OH(b) alkoxy groups containing 1-3 carbon atoms and whereinR.sup.4 is selected from the group consisting of(a) H(b) alkyl groups containing 1-3 carbon atoms, with the proviso that R.sup.3 and R.sup.4 are combined as follows:______________________________________ when R.sup.3 is then is R.sup.

Abstract: A process is disclosed for selectively making trans-cyclohexane-1,4-diisocyanate, trans-cyclohexane-1,4-diamine, a trans-cyclohexane-1,4-diurethane, a transcyclohexane-1,4-diurea and trans-cyclohexane-1,4-disulphonyl urea by reacting ammonia with a mixture of cis and trans cyclohexane-1,4-dicarboxylic acid, a lower alkyl ester, a glycol ester, an oligomeric ester or a polyester to make a solid trans-dicarboxylic acid diamide in a first step. The diamide is chlorinated to form trans-cyclohexane-1,4-dicarboxylic acid-bis-N-chloramide.

Abstract: A synthetic oligodeoxynucleotide complementary to endorphin mRNA and a method of using it to detect and isolate endorphin mRNA and cDNA from human and rabbit pancreas. A unique 15 base oligodeoxynucleotide dCATGAACCCGCCGTA wherein T represents thymine, G represents guanine, A represents adenine, and C represents cytosine and where at least 13 of the 15 nucleotides are as indicated (one of those indicated may be instead one of the other three mentioned nucleotides) has been found to be complementary to endorphin mRNA. To isolate endorphin mRNA, total RNA is first extracted from human brain and A+ is isolated from the total RNA. Other tissues may be used. The A+ RNA is then treated with the oligodeoxynucleotide, and the resulting hybridized RNA is enzymatically converted to endorphin mRNA:cDNA which can then be purified and used in a conventional manner to produce endorphin by cloning techniques.

Abstract: A new antibiotic BMG162-aF2 having the formula ##STR1## can be obtained by cultivating a BMG162-aF2-producing strain belonging to the genus Bacillus in a culture medium to produce and accumulate the said BMG162-aF2 and then recovering it from the culture medium. The antibiotic BMG162-aF2 thus obtained or a pharmaceutically acceptable salt thereof can be used for the treatment of a transplanted tumor in warmblooded animals.

Abstract: Novel uracil derivatives of the formula ##STR1## (wherein R.sub.1, R.sub.2 R.sub.3 and X are defined in the description) and their pharmaceutically acceptable salts, process for preparing the same and pharmaceutical composition containing the same are disclosed. The uracil derivatives have good antitumor activity and, therefore, are useful as antitumor preparation.

Abstract: The present invention provides a pharmaceutical composition for treating ulcerative colitis containing at least one compound of the general formula: ##STR1## wherein X is an --SO.sub.2 -- or --CO-- group and R is either an unsubstituted or substituted non-heterocyclic aromatic ring system or is a radical of the general formula --(CH.sub.2).sub.n --Y, in which Y is a hydroxyl group, an unsubstituted or substituted amino group or a carboxylic or sulphonic acid group and n is a whole number of from 1 to 6 and in which one or more hydrogen atoms in the alkylene radical can be replaced by unsubstituted or substituted amino groups or alkyl radicals and in which the --(CH.sub.2).sub.n --Y radical is either attached directly to the nitrogen atom or via a benzene ring; and/or containing at least one ester thereof and/or at least one non-toxic, pharmaceutically acceptable salt thereof, in admixture with a solid or liquid pharmaceutical diluent or carrier.